Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review1395 has been discontinued.
View all Non-selective Ionotropic Glutamate products.(R)-3,4-DCPG is a AMPA receptor antagonist with weak activity at NMDA receptors and little activity at kainate receptors.
Racemate and S-enantiomer also available.
分子量 | 239.18 |
公式 | C10H9NO6 |
储存 | Desiccate at RT |
纯度 | ≥96% (HPLC) |
CAS Number | 201730-10-1 |
PubChem ID | 6604849 |
InChI Key | IJVMOGKBEVRBPP-SSDOTTSWSA-N |
Smiles | N[C@@]([H])(C(O)=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732 PMID: 11311902
Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111 PMID: 9455991
关键词: (R)-3,4-DCPG, (R)-3,4-DCPG supplier, AMPA, antagonists, weak, NMDA, Glutamate, Ionotropic, Non-Selective, iGlur, Receptors, Non-selective, 1395, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 (R)-3,4-DCPG 的部分引用包括:
Sun et al (2012) Structure based model for the prediction of phospholipidosis induction potential of small molecules. J Chem Inf Model 52 1798 PMID: 22725677
目前没有该产品的评论。 Be the first to review (R)-3,4-DCPG and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.